ERBB2 and gastric cancer: Furthermore, results of clinical trials have shown that the combination of ICIs with chemotherapy [15–19], anti-human epidermal growth factor receptor 2 (HER2) targeted therapy [20], and dual ICIs [21–23], may improve the clinical treatment efficiency of patients with advanced GC.